TransMedics Ownership
| TMDX Stock | USD 68.84 1.49 2.12% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 35.7 M | Current Value 35.2 M | Avarage Shares Outstanding 26.3 M | Quarterly Volatility 7 M |
TransMedics |
TransMedics Stock Ownership Analysis
About 97.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company was founded in 1998 and is headquartered in Andover, Massachusetts. Transmedics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 148 people. To find out more about TransMedics Group contact the company at (978) 552-0900 or learn more at https://www.transmedics.com.Besides selling stocks to institutional investors, TransMedics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different TransMedics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align TransMedics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
TransMedics Quarterly Liabilities And Stockholders Equity |
|
TransMedics Insider Trades History
Roughly 3.0% of TransMedics Group are currently held by insiders. Unlike TransMedics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against TransMedics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of TransMedics' insider trades
TransMedics Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as TransMedics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading TransMedics Group backward and forwards among themselves. TransMedics' institutional investor refers to the entity that pools money to purchase TransMedics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Amvescap Plc. | 2024-12-31 | 678.6 K | Eventide Asset Management, Llc | 2024-12-31 | 677.7 K | Liontrust Investment Partners Llp | 2024-12-31 | 596.4 K | Ubs Group Ag | 2024-12-31 | 590.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 454.4 K | Wasatch Advisors Lp | 2024-12-31 | 441.4 K | Goldman Sachs Group Inc | 2024-12-31 | 420.8 K | Man Group Plc | 2024-12-31 | 395.4 K | Emerald Advisers, Llc | 2024-12-31 | 371.7 K | Blackrock Inc | 2024-12-31 | 5.2 M | Fmr Inc | 2024-12-31 | 4 M |
TransMedics Group Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific TransMedics insiders, such as employees or executives, is commonly permitted as long as it does not rely on TransMedics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases TransMedics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
TransMedics Outstanding Bonds
TransMedics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. TransMedics Group uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most TransMedics bonds can be classified according to their maturity, which is the date when TransMedics Group has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
TransMedics Corporate Filings
F4 | 5th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 6th of December 2024 Other Reports | ViewVerify | |
10Q | 29th of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for TransMedics Stock Analysis
When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.